{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:07:44Z","timestamp":1771484864687,"version":"3.50.1"},"reference-count":30,"publisher":"Oceanside Publications Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Food Allergy"],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:p>The goal of allergen-specific immunotherapy for treatment of immunoglobulin E (IgE) mediated food allergy is to safely and effectively modify the allergic response, providing protection against anaphylaxis via ongoing exposure to the triggering allergen. Targeted allergen exposure <jats:italic>via<\/jats:italic>\n application of allergen to the epidermis has emerged as a potentially promising approach to desensitization. Epicutaneous immunotherapy (EPIT) uses allergen embedded on an adhesive patch secured to the skin. This allows for long-lasting allergen exposure, with subsequent antigen uptake and\n trafficking by skin antigen\u2010presenting cells to regional lymph nodes, which produce immunomodulatory effects in a manner that is noninvasive and limits exposure of allergen to the systemic circulation when applied to intact skin. As such, EPIT is overall well tolerated; local application\n site reactions are common, but systemic adverse effects are infrequent compared with other forms of immunotherapy. For peanut allergy, EPIT may increase the dose-triggering threshold in some individuals with peanut-allergy, especially younger children, but induction of remission has not been\n closely studied, and reliable predictors of clinical response are lacking. With U.S. Food and Drug Administration approved treatment for peanut allergy now available, the precepts of shared decision-making will be crucial in discussions with patients and their families with regard to treatment\n options.<\/jats:p>","DOI":"10.2500\/jfa.2020.2.200016","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T04:40:03Z","timestamp":1598935203000},"page":"81-85","source":"Crossref","is-referenced-by-count":8,"title":["Food allergy: Epicutaneous immunotherapy"],"prefix":"10.2500","volume":"2","author":[{"given":"Timothy G.","family":"Chow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Parrish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Andrew","family":"Bird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.2500\/jfa.2020.2.200028","article-title":"Food allergy: epidemiology and racial\/ethnic differences","volume":"2","author":"Jiang","year":"2020","journal-title":"J Food Allergy"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.2500\/jfa.2020.2.200002","article-title":"Clinical manifestations of IgE-mediated food allergy","volume":"2","author":"Varshney","year":"2020","journal-title":"J Food Allergy"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jaci.2014.05.013","article-title":"Food allergy: a practice parameter update-2014","volume":"134","author":"Sampson","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40413-018-0215-2","article-title":"Skin as an immune organ and clinical applications of skin-based immunotherapy","volume":"11","author":"Bird","year":"2018","journal-title":"World Allergy Organ J"},{"key":"B5","first-page":"1251","article-title":"Asthme d\u2019origine \u00e9quine. Essai de d\u00e9sensibilisation par des cutir\u00e9actions r\u00e9p\u00e9t\u00e9es [desensitization test by repeated skin reactions]","volume":"45","author":"Vallery-Radot","year":"1921","journal-title":"Bull Soc M\u00e9d H\u00f4p Paris"},{"key":"B6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2045-7022-2-22","article-title":"Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice","volume":"2","author":"Mondoulet","year":"2012","journal-title":"Clin Transl Allergy"},{"key":"B7","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/cea.12312","article-title":"The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long-term protection from eosinophilic disorders in peanut-sensitized mice","volume":"44","author":"Dioszeghy","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"B8","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.4049\/jimmunol.1003134","article-title":"Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice","volume":"186","author":"Dioszeghy","year":"2011","journal-title":"J Immunol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaci.2016.03.057","article-title":"Epicutaneous immunotherapy induces gastrointestinal LAP+ regulatory T cells and prevents food-induced anaphylaxis","volume":"139","author":"Tordesillas","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2018.01951","article-title":"Antigen uptake by Langerhans cells is required for the induction of regulatory T cells and the acquisition of tolerance during epicutaneous immunotherapy in OVA-sensitized mice","volume":"9","author":"Dioszeghy","year":"2018","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/cmi.2016.14","article-title":"Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut","volume":"14","author":"Dioszeghy","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/all.13479","article-title":"Gata3 hypermethylation and Foxp3 hypomethylation are associated with sustained protection and bystander effect following epicutaneous immunotherapy in peanut-sensitized mice","volume":"74","author":"Mondoulet","year":"2019","journal-title":"Allergy"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jaci.2014.11.028","article-title":"Specific epicutaneous immunotherapy prevents sensitization to new allergens in a murine model","volume":"135","author":"Mondoulet","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2018.10.025","article-title":"Epicutaneous immunotherapy for peanut allergy modifies IgG4 responses to major peanut allergens","volume":"143","author":"Koppelman","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B15","first-page":"597","article-title":"Delivery of allergen powder for safe and effective epicutaneous immunotherapy","author":"Yu","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jaci.2010.02.029","article-title":"Cow\u2019s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity","volume":"125","author":"Dupont","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B17"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jaci.2016.01.008","article-title":"Safety of epicutaneous immunotherapy for the treatment of peanut allergy: a phase 1 study using the Viaskin patch","volume":"137","author":"Jones","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.jaci.2016.08.017","article-title":"Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults","volume":"139","author":"Jones","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1001\/jama.2017.16591","article-title":"Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial","volume":"318","author":"Sampson","year":"2017","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jama.2019.1113","article-title":"Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial","volume":"321","author":"Fleischer","year":"2019","journal-title":"JAMA"},{"key":"B22"},{"key":"B23"},{"key":"B24"},{"key":"B25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaip.2017.05.006","article-title":"Quantitative assessment of the safety benefits associated with increasing clinical peanut thresholds through immunotherapy","volume":"6","author":"Baumert","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.anai.2019.08.007","article-title":"Estimated risk reduction to packaged food reactions by epicutaneous immunotherapy (EPIT) for peanut allergy","volume":"123","author":"Remington","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.cgh.2019.05.014","article-title":"Efficacy of epicutaneous immunotherapy in children with milk-induced eosinophilic esophagitis","volume":"18","author":"Spergel","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.2500\/jfa.2020.2.200005","article-title":"Food allergy oral immunotherapy","volume":"2","author":"Sood","year":"2020","journal-title":"J Food Allergy"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.2500\/jfa.2020.2.200009","article-title":"Shared decision making in food allergy management","volume":"2","author":"Patrawala","year":"2020","journal-title":"J Food Allergy"},{"key":"B30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.iac.2019.09.004","article-title":"Food allergy immunotherapy with adjuvants","volume":"40","author":"Nicolaides","year":"2020","journal-title":"Immunol Allergy Clin North Am"}],"container-title":["Journal of Food Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/jfa\/2020\/00000002\/00000001\/art00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T09:08:48Z","timestamp":1718010528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/jfa.2020.2.200016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,9,1]]}},"alternative-id":["2689-0267(20200901)2:1L.81;1-"],"URL":"https:\/\/doi.org\/10.2500\/jfa.2020.2.200016","relation":{},"ISSN":["2689-0267"],"issn-type":[{"value":"2689-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}